Absci (ABSI) Accounts Payable : $1.65 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Absci Accounts Payable?

Absci's Accounts Payable for the quarter that ended in Mar. 2024 was $1.65 Mil.

Absci's quarterly Accounts Payable declined from Sep. 2023 ($1.91 Mil) to Dec. 2023 ($1.50 Mil) but then increased from Dec. 2023 ($1.50 Mil) to Mar. 2024 ($1.65 Mil).

Absci's annual Accounts Payable declined from Dec. 2021 ($8.39 Mil) to Dec. 2022 ($2.41 Mil) and declined from Dec. 2022 ($2.41 Mil) to Dec. 2023 ($1.50 Mil).

Absci Accounts Payable Historical Data

The historical data trend for Absci's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Absci Accounts Payable Chart

Absci Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

0.27

2.12

8.39

2.41

1.50

Absci Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial													1.93	1.85	1.91	1.50	1.65

Absci Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Absci Accounts Payable Related Terms

Thank you for viewing the detailed overview of Absci's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Absci (ABSI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683

Website

https://www.absci.com

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Executives

Frans Van Houten	director	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj	director	400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman	officer: General Counsel	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick	officer: VP, CCPAO	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh	director	C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Sean Mcclain	director, 10 percent owner, officer: President and Chief Executive	18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Zachariah Jonasson	director	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Karen K Mcginnis	director	INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p.	director, 10 percent owner	LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc	10 percent owner	1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402
Nikhil Goel	officer: Chief Business Officer	101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660